Recurred. How does this change my treatment choices, and are new targeted therapies using biomarkers (CD20, PD-L1)...

I understand this is concerning news about your lymphoma recurring. Let me provide some evidence-based information about current treatment options.

According to the NCCN Guidelines for Relapsed/Refractory Lymphoma (2023), treatment options depend on several factors, including:

• The specific type of lymphoma you have
• Time since your previous treatment
• Your overall health and ability to tolerate different therapies
• Results of biomarker testing

The Leukemia & Lymphoma Society (LLS) highlights several targeted therapy options based on biomarkers:

• For CD20-positive lymphomas: newer anti-CD20 antibodies like obinutuzumab
• For relapsed cases expressing PD-L1: checkpoint inhibitors like pembrolizumab
• CAR T-cell therapy for certain types of relapsed lymphoma

ASCO Guidelines (2023) recommend comprehensive biomarker testing at relapse because:

1. Your lymphoma's biomarker status may have changed
2. New targeted therapy options may have become available since your initial treatment
3. This information helps determine the most effective treatment approach

It's essential to discuss with your healthcare team to:

• Get appropriate biomarker testing
• Review all available treatment options
• Consider clinical trial opportunities

Would you like me to provide more specific information about any particular treatment approach or biomarker? Please note that treatment recommendations should come from your healthcare team, as they understand your complete medical history.